Related Experiment Videos
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization
Bernd B Zeisig1, Tom Milne, María-Paz García-Cuéllar
1Department of Genetics, University Erlangen, Staudtstrasse 5, 91058 Erlangen, Germany.
Molecular and Cellular Biology
|January 1, 2004
Summary
MLL fusion proteins drive aggressive leukemias by activating specific homeobox genes. This study shows MLL fusion proteins reversibly block myeloid differentiation, offering potential therapeutic targets.
Area of Science:
- Molecular Biology
- Hematology
- Oncology
Background:
- Mixed-lineage leukemia (MLL) fusion proteins are key oncogenic drivers in aggressive lymphoid and myeloid leukemias.
- Understanding the precise molecular mechanisms of MLL-driven leukemogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of MLL fusion proteins in regulating hematopoietic cell proliferation and differentiation.
- To identify specific downstream targets of MLL fusion proteins involved in leukemic transformation.
Main Methods:
- Construction of an inducible MLL fusion protein (MLL-ENL-ERtm) dependent on 4-hydroxy-tamoxifen.
- Culturing and analysis of MLL-ENL-ERtm-immortalized hematopoietic cells.
- Microarray analysis to identify upregulated genes and Hox coregulators.
Main Results:
- MLL-ENL-ERtm expression induced continuous hematopoietic cell growth, dependent on 4-hydroxy-tamoxifen.
- Tamoxifen withdrawal led to terminal differentiation, indicating a reversible block.
- Key targets identified include Hoxa9, Hoxa7, Meis1, and Pbx3; overexpression of Hoxa9 and Meis1 mimicked MLL-ENL-ERtm's transforming activity.
Conclusions:
- MLL fusion proteins induce a reversible block in myeloid differentiation by aberrantly activating specific homeobox genes and Hox coregulators.
- These findings highlight a critical pathway in MLL-associated leukemias and suggest potential therapeutic strategies targeting Hox gene regulation.